FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983425734> ?p ?o ?g. }

• W1983425734 endingPage "1756" @default.
• W1983425734 startingPage "1749" @default.
• W1983425734 abstract "The therapeutic efficacies of human recombinant alpha interferon (IFN-alpha), IFN-alpha plus zidovudine (AZT), and AZT alone were evaluated in presymptomatic cats with established feline leukemia virus (FeLV)-acquired immunodeficiency syndrome (FAIDS) infection and high levels of persistent antigenemia. Subcutaneous injection of 1.6 x 10(6) U of human recombinant IFN-alpha 2b per kg delivered peak concentrations in plasma of 3,600 U/ml at 2 h postadministration with a half-life of elimination of 2.9 h. This dosage of IFN-alpha could be delivered to cats for up to 12 weeks without significant clinical toxicity. Oral administration of AZT (20 mg/kg three times daily) resulted in peak concentrations in plasma of 3 micrograms/ml at 2 h with a half-life of elimination of approximately 1.60 h. Treatment of FeLV-FAIDS-infected cats with IFN-alpha, either alone or in combination with orally administered AZT, resulted in significant decreases in circulating p27 core antigen beginning 2 weeks after the initiation of therapy. AZT alone had no effect on circulating virus antigen. Depending upon whether high (1.6 x 10(6) U/kg)- or low (1.6 x 10(4) to 1.6 x 10(5) U/kg)-dosage IFN-alpha was used, cats became refractory to therapy 3 or 7 weeks after the beginning of treatment. At these times, IFN-alpha-treated animals developed antibodies to IFN-alpha that were neutralizing, specific for human recombinant IFN-alpha, and dose dependent in magnitude. The results of this study indicate that human recombinant IFN-alpha is effective in reducing circulating virus antigenic load in cats persistently infected with FeLV-FAIDS. However, the continued efficacy of IFN-alpha therapy appeared to be limited by the formation of cytokine-specific neutralizing antibodies." @default.
• W1983425734 created "2016-06-24" @default.
• W1983425734 creator A5008370661 @default.
• W1983425734 creator A5028336562 @default.
• W1983425734 creator A5038555695 @default.
• W1983425734 creator A5059070726 @default.
• W1983425734 creator A5061489103 @default.
• W1983425734 creator A5091741532 @default.
• W1983425734 date "1990-09-01" @default.
• W1983425734 modified "2023-10-11" @default.
• W1983425734 title "Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome" @default.
• W1983425734 cites W1503959924 @default.
• W1983425734 cites W1550814250 @default.
• W1983425734 cites W160599993 @default.
• W1983425734 cites W1739595091 @default.
• W1983425734 cites W1975403569 @default.
• W1983425734 cites W1977355715 @default.
• W1983425734 cites W1980259340 @default.
• W1983425734 cites W1993398279 @default.
• W1983425734 cites W1993457223 @default.
• W1983425734 cites W1999381784 @default.
• W1983425734 cites W2004430004 @default.
• W1983425734 cites W2010451278 @default.
• W1983425734 cites W2013749805 @default.
• W1983425734 cites W2020810119 @default.
• W1983425734 cites W2021647664 @default.
• W1983425734 cites W2028331353 @default.
• W1983425734 cites W2040379360 @default.
• W1983425734 cites W2042411177 @default.
• W1983425734 cites W2050600382 @default.
• W1983425734 cites W2053905319 @default.
• W1983425734 cites W2055137465 @default.
• W1983425734 cites W2065235873 @default.
• W1983425734 cites W2077468566 @default.
• W1983425734 cites W2085171161 @default.
• W1983425734 cites W2086186867 @default.
• W1983425734 cites W2086462809 @default.
• W1983425734 cites W2088255505 @default.
• W1983425734 cites W2090507582 @default.
• W1983425734 cites W2090535833 @default.
• W1983425734 cites W2097160811 @default.
• W1983425734 cites W2104527114 @default.
• W1983425734 cites W2105328789 @default.
• W1983425734 cites W2108025620 @default.
• W1983425734 cites W2111449967 @default.
• W1983425734 cites W2114279162 @default.
• W1983425734 cites W2116464980 @default.
• W1983425734 cites W2129816627 @default.
• W1983425734 cites W213803043 @default.
• W1983425734 cites W2143773220 @default.
• W1983425734 cites W2151337540 @default.
• W1983425734 cites W2157245147 @default.
• W1983425734 cites W2167444215 @default.
• W1983425734 cites W2198415354 @default.
• W1983425734 cites W2283390921 @default.
• W1983425734 cites W2327527388 @default.
• W1983425734 cites W2412947976 @default.
• W1983425734 cites W2415467268 @default.
• W1983425734 cites W2466584018 @default.
• W1983425734 cites W3028044011 @default.
• W1983425734 doi "https://doi.org/10.1128/aac.34.9.1749" @default.
• W1983425734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/171917" @default.
• W1983425734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2178336" @default.
• W1983425734 hasPublicationYear "1990" @default.
• W1983425734 type Work @default.
• W1983425734 sameAs 1983425734 @default.
• W1983425734 citedByCount "58" @default.
• W1983425734 countsByYear W19834257342012 @default.
• W1983425734 countsByYear W19834257342013 @default.
• W1983425734 countsByYear W19834257342014 @default.
• W1983425734 countsByYear W19834257342015 @default.
• W1983425734 countsByYear W19834257342016 @default.
• W1983425734 countsByYear W19834257342019 @default.
• W1983425734 countsByYear W19834257342020 @default.
• W1983425734 countsByYear W19834257342021 @default.
• W1983425734 countsByYear W19834257342022 @default.
• W1983425734 crossrefType "journal-article" @default.
• W1983425734 hasAuthorship W1983425734A5008370661 @default.
• W1983425734 hasAuthorship W1983425734A5028336562 @default.
• W1983425734 hasAuthorship W1983425734A5038555695 @default.
• W1983425734 hasAuthorship W1983425734A5059070726 @default.
• W1983425734 hasAuthorship W1983425734A5061489103 @default.
• W1983425734 hasAuthorship W1983425734A5091741532 @default.
• W1983425734 hasBestOaLocation W19834257342 @default.
• W1983425734 hasConcept C104317684 @default.
• W1983425734 hasConcept C126322002 @default.
• W1983425734 hasConcept C159047783 @default.
• W1983425734 hasConcept C203014093 @default.
• W1983425734 hasConcept C2522874641 @default.
• W1983425734 hasConcept C2776178377 @default.
• W1983425734 hasConcept C2779692357 @default.
• W1983425734 hasConcept C2779904517 @default.
• W1983425734 hasConcept C2780216070 @default.
• W1983425734 hasConcept C2780727368 @default.
• W1983425734 hasConcept C2781228144 @default.
• W1983425734 hasConcept C2909179924 @default.
• W1983425734 hasConcept C40767141 @default.
• W1983425734 hasConcept C55493867 @default.

• next